Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652496 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 249
- Enrollment target
NCT00652496: Completed Phase 2 study, sponsored by Allergan.
NCT00652496 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 249 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00652496, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 249 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of each patient
Interventions
- DRUG Bimatoprost 0.01% ophthalmic solution
- DRUG Bimatoprost 0.015% formulation 1 ophthalmic solution
- DRUG Bimatoprost 0.015% formulation 2 ophthalmic solution
- DRUG Bimatoprost 0.02% ophthalmic solution
- DRUG Bimatoprost 0.03% ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
What the finished NCT00652496 record still lists
NCT00652496 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 5 interventions - of which Bimatoprost 0.01% ophthalmic solution is the first listed.
NCT00652496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00652496 about?
NCT00652496 is a clinical study titled "Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension". This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of ea...
What is the current status of trial NCT00652496?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 249 participants. The study started on 2005-01. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00652496?
The interventions under investigation include: Bimatoprost 0.01% ophthalmic solution (DRUG), Bimatoprost 0.015% formulation 1 ophthalmic solution (DRUG), Bimatoprost 0.015% formulation 2 ophthalmic solution (DRUG), Bimatoprost 0.02% ophthalmic solution (DRUG), Bimatoprost 0.03% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00652496?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00652496's enrollment target sits among peer trials
249 233rd of 2000 higher than 1,767 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia